Parexel

Parexel's Martine Folkertsma reminds us of the importance of 'showing up with mildness' in our high-pressure work environments and recommends four simple strategies to cultivate a more positive and productive workplace:   🕰 Practice patience 👂 Listen actively 🤔 Turn on curiosity ❔ Invite diverse perspectives   How do you bring mildness into your workplace? Share your thoughts below!

We were glad to have the opportunity to present at the 2024 #KoNECT International Conference! 🎆 Scroll through the pictures below to see our thought leaders in action 📷 Sinan B. Sarac (MD, MSc, PhD), SVP, Head of Regulatory Strategy Europe at Parexel, hosted a presentation on the latest #EMA updates and the implications posed for drug developers. Baljit (Boo) Samra, EVP, Global Clinical Operations at Parexel, presented on how remote monitoring and digital technologies are reshaping traditional monitoring practices. Thank you to all who visited our booth and joined our presentations! We look forward to continuing these great conversations and partnerships 🤝 #KoNECT2024 #MOHW #MFDS #ClinicalResearch

"There is an ongoing unmet medical need for new and effective therapies to treat mood and other psychiatric disorders." With excitement around the possibility of psychedelics being approved medical treatments, there are significant regulatory challenges to overcome. In this article from our report "Accelerating the new frontiers in neuroscience," Parexel clinical experts Mohit V., Mwango Kashoki MD MPH and Simona Stankeviciute explore recent #FDA and #EMA responses and identify five key strategies to maximize the likelihood of clinical development and regulatory success. Learn how to manage the regulatory risks when developing psychedelics for psychiatric conditions and gaining approval 🔗 https://lnkd.in/eUaJq62R #Neuro #Neuroscience #Neurology #Psychedelics #Regulatory

🕯 Today marks Transgender Day of Remembrance. 🕯 We honor and mourn those who've lost their lives to anti-transgender violence and reflect on the ongoing struggles faced by the transgender community. Healthcare inequities, housing insecurity, employment challenges and personal safety threats are just some of the hardships transgender individuals experience. At Parexel, we're committed to supporting our transgender colleagues, fostering an environment of safety and inclusion. Want to be a better ally? Check out some of the resources we shared internally with all Parexel colleagues today: 🔹 Master more inclusive language: https://brnw.ch/21wOOjD 🔹 Learn more about the violence and threats faced by transgender people in the U.S. and many other countries: https://brnw.ch/21wOOjE 🔹 Consider joining the Human Rights Campaign's webinar on supporting gender expansive youth today at 4 p.m. ET: https://brnw.ch/21wOOjC #TDOR #TransDayOfRemembrance #TransRightsAreHumanRights

Knowing that novel therapies often don't meet their timelines and revenue expectations, our team investigates the business-critical decisions that can de-risk phase 3 trials and accelerate time to market. In this edition of the New Medicines, Novel Insights newsletter, hear from Paul Bridges and a team of Parexel regulatory, market access and biostatistical experts as they explore considerations to de-risk trials through advanced planning and adaptive trial design. Create success by planning for it. Read our latest #NovelInsights article below and subscribe to stay up to date with our weekly newsletter. #ParexelBiotech #DrugDevelopment #ClinicalResearch #ClinicalTrials

We're on the cusp of transformative breakthroughs in understanding and treating neurological disorders. Mirroring past accelerations in cardiology and oncology, decades of incremental advances, coupled with growing urgency due to rising global disease burdens, are driving progress. In this article, part of our recent New Medicines, Novel Insights report "Accelerating the new frontiers in neuroscience," Andreas Lysandropoulos MD, PhD highlights the challenges and immense opportunity in the clinical neuroscience landscape. Discover Andreas' insights on what is holding progress back and the drivers that will carry this critical research forward, revolutionizing patient care and treatment options. 🔗 https://lnkd.in/eBZV7vkU #NovelInsights #Neuroscience #ClinicalResearch #PatientsFirst 

As part of STAT’s "Who to Know" series, health tech correspondent Katie Palmer spoke to 6 companies — including our own Stephen Pyke — highlighting how the adoption of AI and machine learning is proving to be a game changer in streamlining processes and automating key administrative aspects of clinical trials. Let’s keep the conversation going: How do you see AI reshaping clinical research in the coming years? Check out the full article from STAT to find out more about Parexel's AI applications and what the other companies featured are working on: https://lnkd.in/e_Ar_crG #ClinicalTrials #ArtificialIntelligence #Innovation #Biotech #Pharma Unlearn.AI BioPhy ConcertAI Norstella Insilico Medicine 

Join Parexel to help shape the future of clinical research as a Project Leader! 🔬 Drive innovation 👥 Inspire teams 🤝 Partner with global customers ❤️ Change patient lives. Apply for your next leadership role today. 👉 https://insde.co/hord #ParexelCareers #ClinicalResearchJobs #ProjectManagement

As the 2024 "Shine a Light on Patients" sponsor for The Leukemia & Lymphoma Society in the Triangle, Parexel leaders visited the Duke Cancer Institute to meet patients undergoing cancer treatment and hear their powerful stories. We brought the spirit of #LightTheNight directly to these brave individuals — brightening up their hospital rooms with a special lantern adorned with messages of hope and encouragement from event attendees and light-up items from the in-person walk. 🤍 These moments serve as a profound reminder of why we do what we do at Parexel. Every day, we're driven by the courage and resilience of patients and their families. Together, we hope to illuminate the path to better treatments and brighter futures. 💪💡 Peyton Howell, Scott Smith, Chris A. Learn, Ph.D, PMP, Joseph McFadden, Denise Hull, CCP, GRP 

The Parexel team is headed to Barcelona this weekend for #ISPOREurope 🎊 Don't miss our educational symposium on "Harnessing the power of #AI in #RWD: Enhanced insights through machine learning and causal inference advances." Parexel experts Jacqueline Vanderpuye-Orgle, Katja M Hakkarainen and Andy Wilson will be joined by special guests Patrice Verpillat, Head of Real-World Evidence at EMA and Ipek Özer Stillman, Vice President, Global Head of Health Economics at Takeda, as we explore foundations and advances in causal machine learning methods, focusing on deriving patient insights and improving treatment decision-making. Revolutionize patient outcomes through partnerships that work. Use the following link to schedule a meeting with our attending experts: https://lnkd.in/eaUkEUJi #ISPOR #ISPOREurope2024 #HEOR #AdvancedAnalytics #RWE